972 / 1631
UK
-
BNLI study
•
640 pts, Aggressive, high-grade NHL
•
Consolidation (80%)
•
Definitive (12%)
•
Palliative (8%)
•
Randomized to:
•
40-45
Gy
•
30
Gy
•
Rituximab (~10%)
Freedom from Local Progression
84% vs 82% (5 years)
Radiotherapy & Oncology 2011;100:86